BIOSEAL BIOTECH

Guangzhou Bioseal Biotech is a specialized biotechnology firm focused on the research, development, and commercialization of biological hemostatic products. The company is best known for its flagship product, Bioseal, which is the first porcine-derived fibrin sealant approved in China for surgical use. This biologic product mimics the final stage of the blood coagulation cascade to achieve rapid hemostasis and tissue sealing. Originally established in 2003, the company was a subsidiary of Johnson & Johnson's Ethicon division for a decade before being acquired by Grand Pharmaceutical Group in 2022. Bioseal Biotech continues to lead the Chinese market in absorbable biological materials, providing essential tools for surgeons to manage bleeding and improve patient outcomes.